SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Groupon, Inc. engages in the global scaled two-sided marketplace that connects consumers to merchants. It operates through the North America and International geographical segments. The company was founded by Andrew D. Mason, Eric Paul Lefkofsky, and Bradley A. Keywell in October 2008 and is headquartered in Chicago, IL.

Groupon Inc

Groupon is experiencing a surge in bullish sentiment driven by a combination of a significantly tight float and high short interest that has led investors to draw parallels to other major short squeeze events. The community is actively discussing the stock's potential for a parabolic move, pointing to aggressive share buybacks, internal restructuring efforts toward AI integration, and the mechanical pressure on short sellers as primary catalysts for continued upside.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as retail and institutional investors anticipate significant momentum driven by global expansion efforts and pending near-term catalysts, including potential revenue growth and ongoing international regulatory progress. The community remains highly focused on the company's proprietary immunotherapy platform, expressing strong conviction that institutional accumulation will fuel a potential squeeze against high short interest.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is facing significant downward pressure and intense community scrutiny as investors express frustration over its performance relative to other major assets. Discussions are dominated by accusations of manipulation and project abandonment, with many traders debating the viability of long-term accumulation versus concerns about a potential value trap.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is experiencing significant market interest driven by ongoing momentum in the healthcare AI sector and anticipation surrounding its upcoming investor day. Community discussions are heavily focused on the stock's high short interest and its potential as a long-term play in precision medicine, with many investors closely monitoring volume and institutional accumulation patterns.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is trending as investors react to a significant US commercialization deal with Tolmar, which provides both capital and infrastructure to de-risk the company's oncology platform. The community is actively discussing this validation, the stock's impressive pipeline of clinical trial catalysts, and growing institutional interest despite ongoing market volatility.

UNI is the governance token for Uniswap, an Automated Market Marker DEX on the Ethereum blockchain. The UNI token allows token holders to participate in the governance of the protocol. Key decisions such as usage of the treasury or future upgrades can be decided through a governance vote.

UniSwap

Uniswap is trending as community members closely monitor a governance proposal to activate the protocol's fee switch, which could redirect trading revenue to token holders and implement a significant token burn. Traders are actively debating the potential for this mechanism to improve long-term tokenomics while analyzing technical indicators and recent volume shifts to determine if a sustained price reversal is underway.

Rackspace Technology, Inc. engages in the provision of end-to-end multi-cloud technology services. The firm designs, builds and operates its customers’ cloud environments across technology platforms. It operates through the following segments: Public Cloud and Private Cloud. The Public Cloud segment is a services-centric, capital-light model providing value-added cloud solutions through managed services, Elastic Engineering and professional services offerings for customer environments hosted on the AWS, Microsoft Azure and Google Cloud public cloud platforms. The Private Cloud segment is a technology-forward, capital-intensive model providing managed service offerings for customer environments hosted in data centers as well as in those owned by customers or by third parties such as colocation providers. The company was founded on July 21, 2016 and is headquartered in San Antonio, TX.

Rackspace Technology Inc

Rackspace Technology is currently trending following a definitive agreement with AMD to deploy AI compute infrastructure, a catalyst fueling optimism for its pivot into high-margin enterprise data center services. Community discourse is heavily split between bulls cheering the institutional validation and long-term potential, and bears highlighting the companys significant debt burden and potential for dilution.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

Fubo remains a highly polarized ticker as investors weigh institutional ownership and potential short-squeeze dynamics against persistent concerns over management credibility and ongoing share price decline. The community is actively debating the company's long-term viability, often clashing over whether the stock represents a deep-value turnaround opportunity or a cautionary tale of persistent dilution and leadership distrust.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is gaining traction following the launch of its Data Marketplace, which allows major financial institutions like Fidelity and Euronext to publish proprietary data directly on-chain. Investors are highlighting its role as critical infrastructure for real-world assets and prediction markets, while continuing to debate its utility, revenue-sharing model, and long-term tokenomics.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as investors weigh potential breakthroughs in in-vivo CRISPR gene editing against significant short interest, while the community focuses on upcoming clinical trial data presentations and the long-term potential for commercialized rare disease therapies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PCSA Stock Rallies 10% After Hours— Here’s Why

Equity

According to filings made with the Securities and Exchange Commission, several insiders bought shares of the company at a price of about $2.535 on the last day of March. 


PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study

Processa Pharmaceuticals stock jumps 122% after a phase II update shows NGC-Cap delivers higher active metabolite exposure with comparable safety in breast cancer.

Why Is Small-Cap Processa Pharmaceuticals Stock Rallying After Breast Cancer Trial Data?

Processa Pharmaceuticals' stock jumps after Phase 2 data show higher capecitabine exposure without added toxicity in metastatic breast cancer patients.read more...

Oracle, Hut 8, Processa Pharmaceuticals, Recursion Pharmaceuticals, Udemy: Stocks Making The Biggest Moves Today

Oracle shares were down over 5% in Wednesday’s midday session after Blue Owl Capital reportedly withdrew from a $10 billion investment in the company’s new facility in Saline Township, Michigan.

Why Did Processa Pharmaceuticals Stock Surge 160% Today?

The company announced that early Phase 2 data showed that its NGC therapy increased cancer-fighting metabolites in patients with advanced breast cancer.

Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on March 29, 2011 and is headquartered in Vero Beach, FL.

Processa Pharmaceuticals Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$2.16
Prev Close	$1.96
Open	$2.10
Dividend Yield	0.00%
50-Day Moving Average	$2.49
Beta	1.00
Avg. Volume	63,248.73
PE Ratio	-0.20

52-Week High	$14.24
52-Week Low	$1.76
Market Capitalization	$5.98M
EPS (Annual)	-$10.36
Price to Book	2.28
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

PCSAProcessa Pharmaceuticals Inc

Latest PCSA News